Role of eugenol in reversal of Vascular dysfunction induced by Experimental diabetes and Hypertension

Abstract

Phenylpropanoids are a diverse group of phytochemicals with immense health newlinebenefits and found throughout the plant kingdom. Eugenol is a member of the newlinephenylpropanoids and is remarkably versatile molecule which is present abundantly in newlineclove, nutmeg, cinnamon, basil and bay leaf. Epidemiological evidence and clinical trial newlinedata indicates that due to presence of biologically active phytochemicals, the plant newlineoriginated diets can reduce the risk of chronic disease conditions such as cardiovascular newlinedisease, hypertension, diabetes and cancer. Hypertension and diabetes are the lifestyle newlinediseases which are considered to be main causes of mortality for decades in humans. newlineVascular dysfunction is the major change that is associated with diabetes and newlinehypertension. It is well documented that both diabetes and hypertension occur together newlinein most of the human beings that is an additive cause for increase in risk of vascular newlinecomplications. Though there are standard treatments available at present for these newlinecomplications, a look for an alternative approach that can better address the vascular newlineproblems is most wanted. Hence the present study was designed to know the effect of newlineeugenol against vascular dysfunction associated with either diabetes or hypertension newlinealone and diabetes with hypertension together. newlineThe study was carried out in rats that are divided into eight groups with ten rats newlinein each. Group-I (normal control) received vehicle alone for eight weeks whereas group- newlineII (eugenol control) received eugenol orally and daily at the rate of 80 mg/kg for eight newlineweeks. Group- III, IV and V constitute experimentally induced hypertension control, newlinediabetic control and diabetic rats with hypertension. Hypertension was induced in rats newlinewith administration of L-NAME in drinking water (40 mg/kg/day). Whereas single dose newlineof streptozotocin was injected intraperitoneally at 40 mg/kg for inducing diabetes in newlinerats. Group V rats received both streptozotocin and L-NAME. Group- VI (eugenol newlinetreated hypertensive rats), VII (eugenol treated diabetic